Foghorn Accounts Payable vs Retained Earnings Analysis

FHTX Stock

USD 7.90 0.06 0.77%

Foghorn Therapeutics financial indicator trend analysis is much more than just examining Foghorn Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Foghorn Therapeutics is a good investment. Please check the relationship between Foghorn Therapeutics Accounts Payable and its Retained Earnings accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Accounts Payable vs Retained Earnings

Accounts Payable vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Foghorn Therapeutics Accounts Payable account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.

The correlation between Foghorn Therapeutics' Accounts Payable and Retained Earnings is -0.95. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Foghorn Therapeutics, assuming nothing else is changed. The correlation between historical values of Foghorn Therapeutics' Accounts Payable and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Foghorn Therapeutics are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Accounts Payable i.e., Foghorn Therapeutics' Accounts Payable and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.95

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Foghorn Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Foghorn Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Foghorn Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Foghorn Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.Selling General Administrative is likely to drop to about 19.7 M in 2024. Tax Provision is likely to drop to about 2.3 M in 2024

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.5M	3.3M	3.5M	3.9M
Interest Income	2.6M	5.7M	10.6M	11.1M

Depreciation And Amortization Interest Income

Foghorn Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.86	0.43	0.63	0.55	0.89	0.73	0.93	-0.48	-0.8	0.78	0.7	0.94	0.73	0.71	0.89	0.85	0.8	0.73	0.8	0.94	0.93	0.49	0.96	1.0	0.99
Short Long Term Debt Total	0.86		0.54	0.48	0.68	0.65	0.88	0.98	-0.27	-0.73	0.76	0.57	0.98	0.54	0.62	0.92	0.81	0.85	0.53	0.99	0.92	0.69	0.66	0.78	0.82	0.82
Other Current Liab	0.43	0.54		0.5	0.8	0.12	0.63	0.52	-0.56	-0.03	0.14	0.61	0.53	0.46	0.76	0.39	0.49	0.23	-0.19	0.51	0.39	0.19	0.8	0.27	0.4	0.43
Total Current Liabilities	0.63	0.48	0.5		0.11	0.66	0.18	0.55	-0.95	-0.64	0.67	0.98	0.6	0.98	0.59	0.57	0.84	0.61	0.07	0.46	0.63	0.71	0.06	0.69	0.63	0.62
Total Stockholder Equity	0.55	0.68	0.8	0.11		0.16	0.91	0.65	-0.09	-0.06	0.1	0.26	0.63	0.14	0.7	0.47	0.34	0.26	0.22	0.62	0.47	0.23	1.0	0.32	0.52	0.57
Other Liab	0.89	0.65	0.12	0.66	0.16		0.42	0.76	-0.5	-0.89	0.88	0.66	0.78	0.78	0.48	0.85	0.83	0.79	0.78	0.63	0.89	0.99	0.1	0.98	0.9	0.87
Net Tangible Assets	0.73	0.88	0.63	0.18	0.91	0.42		0.86	-0.06	-0.41	0.41	0.34	0.83	0.27	0.58	0.71	0.56	0.51	0.48	0.85	0.73	0.46	0.89	0.57	0.7	0.73
Property Plant And Equipment Net	0.93	0.98	0.52	0.55	0.65	0.76	0.86		-0.35	-0.79	0.81	0.64	1.0	0.63	0.64	0.95	0.87	0.86	0.61	0.97	0.97	0.79	0.61	0.87	0.9	0.89
Net Debt	-0.48	-0.27	-0.56	-0.95	-0.09	-0.5	-0.06	-0.35		0.41	-0.45	-0.93	-0.41	-0.92	-0.56	-0.36	-0.7	-0.35	0.1	-0.25	-0.44	-0.55	-0.05	-0.52	-0.48	-0.48
Retained Earnings	-0.8	-0.73	-0.03	-0.64	-0.06	-0.89	-0.41	-0.79	0.41		-0.95	-0.64	-0.81	-0.73	-0.27	-0.84	-0.87	-0.88	-0.65	-0.75	-0.9	-0.88	-0.01	-0.9	-0.79	-0.75
Accounts Payable	0.78	0.76	0.14	0.67	0.1	0.88	0.41	0.81	-0.45	-0.95		0.65	0.82	0.74	0.38	0.92	0.89	0.94	0.6	0.79	0.91	0.86	0.07	0.89	0.76	0.71
Cash	0.7	0.57	0.61	0.98	0.26	0.66	0.34	0.64	-0.93	-0.64	0.65		0.69	0.98	0.64	0.61	0.88	0.61	0.1	0.55	0.69	0.71	0.22	0.72	0.7	0.69
Non Current Assets Total	0.94	0.98	0.53	0.6	0.63	0.78	0.83	1.0	-0.41	-0.81	0.82	0.69		0.68	0.66	0.95	0.89	0.87	0.59	0.96	0.97	0.81	0.59	0.88	0.91	0.9
Non Currrent Assets Other	0.73	0.54	0.46	0.98	0.14	0.78	0.27	0.63	-0.92	-0.73	0.74	0.98	0.68		0.58	0.65	0.9	0.64	0.23	0.52	0.73	0.81	0.09	0.79	0.73	0.71
Other Assets	0.71	0.62	0.76	0.59	0.7	0.48	0.58	0.64	-0.56	-0.27	0.38	0.64	0.66	0.58		0.59	0.55	0.54	0.27	0.53	0.57	0.58	0.68	0.59	0.71	0.73
Long Term Debt	0.89	0.92	0.39	0.57	0.47	0.85	0.71	0.95	-0.36	-0.84	0.92	0.61	0.95	0.65	0.59		0.88	0.92	0.67	0.92	0.97	0.85	0.44	0.91	0.86	0.84
Cash And Short Term Investments	0.85	0.81	0.49	0.84	0.34	0.83	0.56	0.87	-0.7	-0.87	0.89	0.88	0.89	0.9	0.55	0.88		0.82	0.41	0.82	0.93	0.84	0.3	0.89	0.83	0.81
Common Stock Shares Outstanding	0.8	0.85	0.23	0.61	0.26	0.79	0.51	0.86	-0.35	-0.88	0.94	0.61	0.87	0.64	0.54	0.92	0.82		0.59	0.85	0.89	0.81	0.23	0.85	0.78	0.75
Non Current Liabilities Total	0.73	0.53	-0.19	0.07	0.22	0.78	0.48	0.61	0.1	-0.65	0.6	0.1	0.59	0.23	0.27	0.67	0.41	0.59		0.49	0.68	0.76	0.17	0.76	0.74	0.72
Other Current Assets	0.8	0.99	0.51	0.46	0.62	0.63	0.85	0.97	-0.25	-0.75	0.79	0.55	0.96	0.52	0.53	0.92	0.82	0.85	0.49		0.91	0.65	0.6	0.75	0.76	0.75
Other Stockholder Equity	0.94	0.92	0.39	0.63	0.47	0.89	0.73	0.97	-0.44	-0.9	0.91	0.69	0.97	0.73	0.57	0.97	0.93	0.89	0.68	0.91		0.9	0.42	0.95	0.92	0.9
Total Liab	0.93	0.69	0.19	0.71	0.23	0.99	0.46	0.79	-0.55	-0.88	0.86	0.71	0.81	0.81	0.58	0.85	0.84	0.81	0.76	0.65	0.9		0.16	0.99	0.94	0.92
Net Invested Capital	0.49	0.66	0.8	0.06	1.0	0.1	0.89	0.61	-0.05	-0.01	0.07	0.22	0.59	0.09	0.68	0.44	0.3	0.23	0.17	0.6	0.42	0.16		0.27	0.47	0.51
Property Plant And Equipment Gross	0.96	0.78	0.27	0.69	0.32	0.98	0.57	0.87	-0.52	-0.9	0.89	0.72	0.88	0.79	0.59	0.91	0.89	0.85	0.76	0.75	0.95	0.99	0.27		0.96	0.94
Total Current Assets	1.0	0.82	0.4	0.63	0.52	0.9	0.7	0.9	-0.48	-0.79	0.76	0.7	0.91	0.73	0.71	0.86	0.83	0.78	0.74	0.76	0.92	0.94	0.47	0.96		1.0
Net Working Capital	0.99	0.82	0.43	0.62	0.57	0.87	0.73	0.89	-0.48	-0.75	0.71	0.69	0.9	0.71	0.73	0.84	0.81	0.75	0.72	0.75	0.9	0.92	0.51	0.94	1.0

Click cells to compare fundamentals

Foghorn Therapeutics Account Relationship Matchups

Foghorn Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.3M	255.6M	519.8M	404.9M	285.9M	280.8M
Short Long Term Debt Total	16.6M	82.0M	58.3M	51.5M	45.1M	47.8M
Other Current Liab	450K	5.2M	2.6M	5.0M	(84K)	(79.8K)
Total Current Liabilities	12.7M	18.8M	48.7M	336.8M	58.4M	87.8M
Total Stockholder Equity	(88.0M)	146.2M	96.9M	112K	(77.2M)	(73.3M)
Net Tangible Assets	(88.0M)	146.2M	96.9M	112K	128.8K	122.4K
Property Plant And Equipment Net	3.7M	62.3M	56.1M	49.4M	42.9M	39.7M
Net Debt	1.6M	(10.8M)	(42.8M)	(294.3M)	(35.3M)	(37.0M)
Retained Earnings	(94.1M)	(162.9M)	(264.3M)	(373.1M)	(471.6M)	(448.0M)
Accounts Payable	3.4M	3.7M	3.8M	5.4M	6.3M	4.5M
Cash	15.0M	92.8M	101.1M	345.8M	80.3M	123.8M
Non Current Assets Total	5.5M	64.9M	60.2M	59.1M	45.7M	43.6M
Non Currrent Assets Other	11K	842K	2.4M	8.0M	2.8M	2.7M
Other Assets	1.7M	2.6M	4.1M	4.1M	1.0	0.95
Cash And Short Term Investments	15.0M	185.8M	154.3M	345.8M	234.1M	178.7M
Common Stock Shares Outstanding	36.8M	36.8M	37.2M	41.6M	42.0M	39.2M
Liabilities And Stockholders Equity	22.3M	255.6M	519.8M	404.9M	285.9M	280.8M
Non Current Liabilities Total	97.7M	90.6M	374.2M	68.0M	304.7M	185.9M
Capital Lease Obligations	1.5M	62.3M	58.3M	51.5M	45.1M	40.1M
Other Current Assets	1.4M	9.8M	5.3M	5.6M	6.1M	5.2M
Other Stockholder Equity	6.1M	309.1M	361.1M	377.2M	395.2M	266.4M
Total Liab	110.4M	109.4M	422.9M	404.8M	363.1M	273.7M
Net Invested Capital	(72.9M)	165.8M	96.9M	112K	(77.2M)	(73.3M)
Property Plant And Equipment Gross	3.7M	19.5M	61.4M	58.0M	54.9M	36.6M
Total Current Assets	16.9M	190.7M	459.6M	345.8M	240.2M	237.1M
Accumulated Other Comprehensive Income	(86.6M)	(7K)	(10K)	(4.0M)	(826K)	(867.3K)
Net Working Capital	4.2M	171.8M	410.9M	296.2M	181.7M	202.0M
Property Plant Equipment	3.7M	62.3M	56.1M	49.4M	56.8M	38.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Foghorn Accounts Payable vs Retained Earnings Analysis

Accounts Payable vs Retained Earnings

Accounts Payable vs Retained Earnings Correlation Analysis

Correlation Coefficient

Accounts Payable

Retained Earnings

Foghorn Therapeutics fundamental ratios Correlations

Foghorn Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Foghorn Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Foghorn Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Net Working Capital	+ 1.0	Total Current Assets
Net Working Capital	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Short Long Term Debt Total

Accounts Payable	- 0.95	Retained Earnings
Net Debt	- 0.95	Total Current Liabilities
Cash	- 0.93	Net Debt
Non Currrent Assets Other	- 0.92	Net Debt
Property Plant And Equipment Gross	- 0.9	Retained Earnings
Other Stockholder Equity	- 0.9	Retained Earnings